INDIA – Global technology company ABB India Limited has bagged a lucrative automation contract with Reliance Life Sciences (RLS) for an undisclosed amount.

Under the terms of the new contract, ABB India has been tapped to automate Reliance Life Sciences’ new manufacturing plants in the city of Nashik in Maharashtra.

The objective is to systematically automate a wide range of distinct and complex unit operations involved in the production of biotechnology products at RLS’ facilities.

In a press statement, KV Subramaniam, President of Reliance Life Sciences, said: “Reliance Life Sciences has a tradition of leveraging automation technologies in its manufacturing processes as part of its larger objectives in quality and productivity.”

RLS’ 160-acre site at Nashik will house manufacturing plants for plasma proteins, biopharmaceuticals, oncology pharmaceuticals, and vaccines.

Large-scale biotechnology production presents distinct and complex process and automation challenges.

These processes adhere to strict regulatory guidelines to ensure product quality, and ABB’s System 800xA solution reduces manufacturing errors and ensures high-quality yields.

On his part, G Balaji, Senior Vice President and Head of the Energy Industries division at ABB India, stated: “We are proud to partner with Reliance Life Sciences on this critical project. This collaboration will reinforce our position in the pharma and life sciences market, where, as a technology provider, we see tremendous potential for growth and innovation.”

ABB India Limited is an integrated power equipment manufacturer supplying a complete range of engineering, products, solutions, and services in areas of Automation and Power technology.

One of its key solutions is the flagship Distributed Control System (DCS) Ability System 800xA, Remote I/O systems, Batch Recipe Management, and MES Integration.

Its flagship system connects seamlessly with various skid systems and is used extensively for seamless operator interaction, batch control, and production information on the factory floor.

Owing to this, ABB India Limited is gearing up to deploy automation and control solutions for RLS’ new biosimilars and plasma proteins manufacturing facilities in Nashik.

G Balaji further disclosed that ABB’s System 800xA will be installed in a virtualized environment for RLS’s new manufacturing facilities in Nashik.

The scope of the work involves complete automation of the manufacturing process using ABB’s flagship DCS Ability System 800xA solution.

ABB will deliver the DCS on the latest Windows Server 2022 platform, which will ensure extended lifecycle support and best-in-class software management.

By integrating ABB’s tech-driven solution within its units at the manufacturing plant in Nashik, Reliance Life Sciences is well-positioned to prioritize high-value operations related to biotechnology production.

This integration not only ensures a unified audit trail, integrated data reports, and streamlined operations, reducing maintenance, training needs, and inventory but also simplifies third-party audits.

The integration will also allow RLS’ manufacturing facilities to achieve faster commissioning and process implementation with the ability to scale the capacity of the plant in the future.

Commenting on the significance of automating biotech production processes: G Balaji stated: “With India rapidly progressing as a prominent biopharmaceutical manufacturing hub, we find ourselves well-poised to ride the wave of the industrial revolution driven by the adoption of automation in these segments, which is pivotal for large-scale production with quality assurance.”

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.